Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature

Ito, Kenichi; Nishiyama, Risa; Hirano, Kazuhiko; Yamada, Kazuo; Sekiguchi, Naohiro

doi:10.5045/br.2019.54.3.236

Cited by 2 publications

(2 citation statements)

References 14 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these, bendamustine-rituximab and bortezomib-dexamethasone-rituximab combinations were associated with higher response rates and longer survival when compared with cyclophosphamide-dexamethasone-rituximab [ 12 , 13 ] . Ito et al reported successful treatment of two MYD88 L265P-mutation-negative non-IgM LPL cases with bortezomib-containing regimens [ 14 ] . In patients with the MYD88 L265P mutation, ibrutinib is an effective treatment option as this mutation triggers survival signalling through BTK and HCK, and the cell lines expressing it undergo apoptosis in response to ibrutinib, which targets both of these kinases [ 15 ] .…”

Section: Discussionmentioning

confidence: 99%

Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression

Cautha

Gupta

Ahnif

et al. 2022

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Introduction: Lymphoplasmacytic lymphoma (LPL) is a rare low-grade B-cell neoplasm that accounts for approximately 2% of all haematological malignancies. Most patients have the clinical syndrome of Waldenstrom macroglobulinemia (WM), which is defined as LPL with an associated immunoglobulin M (IgM) serum monoclonal protein. Roughly 5% of LPL patients secrete non-IgM paraproteins (e.g., IgG, IgA, kappa, lambda) or are non-secretory. Case description: We report the case of a 41-year-old woman who was diagnosed with non-IgM LPL with lambda light chain monoclonal paraprotein production and normal serum immunoglobulin levels. The MYD88 L265P mutation was detected on fluorescence in-situ hybridization (FISH) analysis of the bone marrow. The patient underwent treatment with a combination of ibrutinib and rituximab. There was an initial response but she died 8 months after diagnosis. Discussion: Non-IgM LPL poses diagnostic and therapeutic challenges to clinicians as it is an exceptionally rare malignancy with a heterogeneous clinicopathological presentation and scarce literature. Among non-IgM LPL cases, those with lambda light chain production are even more rare. To the best of our knowledge, none have been reported to date. The addition of MYD88 L265P testing to the diagnostic armamentarium of non-IgM LPL cases is advisable for potential therapeutic reasons.

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression

Cautha

Gupta

Ahnif

et al. 2022

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

show abstract

“…MTX, a type-2 DNA topoisomerase inhibitor [9], has been widely used as chemotherapy for the treatment of metastatic prostate cancer [10,11]. Bortezomib (BZM; PS-341) is a boronic acid dipeptide that inhibits 26S proteasome activity [12], which provides clinical benefits for patients with hematological malignancies, including multiple myeloma [13] and mantle cell lymphoma [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells

et al. 2021

View full text Add to dashboard Cite

Background Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown. Methods Anticancer effects of combination of BZM and MTX were determined by apoptosis and proliferation assay in vivo and in vitro. Expression of β-Catenin and its target genes were characterized by western blot and Real-time PCR. Results BZM significantly enhanced MTX-induced antiproliferation in vivo and in vitro. Mice administered a combination of BZM and MTX displayed attenuated tumor growth and prolonged survival. BZM significantly attenuated MTX-induced apoptosis. Moreover, the combination of BZM and MTX contributed to inhibition of the Wnt/β-Catenin signaling pathway compared to monotherapy. Conclusions This study demonstrates that BZM enhances MTX-induced anti-tumor effects by inhibiting the Wnt/β-Catenin signaling pathway in prostate cancer cells.

show abstract

Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature

Cited by 2 publications

References 14 publications

Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression

Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells

Contact Info

Product

Resources

About